Acyclovir and Transmission of HIV-1 from Persons Infected with HIV-1 and HSV-2
作者： Allison H. Ruark , James D. Shelton , Daniel T. Halperin
关键词: Viral disease 、 Internal medicine 、 Lentivirus 、 Sida 、 Adverse effect 、 Acquired immunodeficiency syndrome (AIDS) 、 Aciclovir 、 Virology 、 Relative risk 、 Pharmacotherapy 、 Medicine
摘要: per milliliter (95% CI, 0.22 to 0.29; P<0.001) and the occurrence of HSV-2–positive genital ulcers by 73% (risk ratio, 0.27; 95% 0.20 0.36; P<0.001). A total 92% partners infected with HIV-1 84% not remained in study for 24 months. The level adherence dispensed drug was 96%. No serious adverse events related acyclovir were observed. Conclusions Daily therapy did reduce risk transmission HIV-1, despite a reduction plasma RNA 0.25 log 10 copies due HSV-2. (ClinicalTrials.gov number, NCT00194519.)
cabdirect.org
harvard.edu
lshtm.ac.uk
sci-hub.se 参考文章(35)
Helen Weiss, Epidemiology of herpes simplex virus type 2 infection in the developing world. Herpes. ,(2004)
Timothy Schacker, Judith Zeh, Huilin Hu, Mary Shaughnessy, Lawrence Corey, Changes in Plasma Human Immunodeficiency Virus Type 1 RNA Associated with Herpes Simplex Virus Reactivation and Suppression The Journal of Infectious Diseases. ,vol. 186, pp. 1718- 1725 ,(2002) , 10.1086/345771
Sinéad Delany, Nonkululeko Mlaba, Tim Clayton, Godspower Akpomiemie, Alexio Capovilla, Jerome Legoff, Laurent Belec, Wendy Stevens, Helen Rees, Philippe Mayaud, Impact of aciclovir on genital and plasma HIV-1 RNA in HSV-2/HIV-1 co-infected women: a randomized placebo-controlled trial in South Africa. AIDS. ,vol. 23, pp. 461- 469 ,(2009) , 10.1097/QAD.0B013E32831DB217
Judith R Glynn, Samuel Biraro, Helen A Weiss, Herpes simplex virus type 2: a key role in HIV incidence. AIDS. ,vol. 23, pp. 1595- 1598 ,(2009) , 10.1097/QAD.0B013E32832E15E8
Judd L Walson, Phelgona A Otieno, Margaret Mbuchi, Barbra A Richardson, Barbara Lohman-Payne, Steve Wanyee Macharia, Julie Overbaugh, James Berkley, Eduard J Sanders, Michael H Chung, Grace C John-Stewart, Albendazole treatment of HIV-1 and helminth co-infection: a randomized, double-blind, placebo-controlled trial. AIDS. ,vol. 22, pp. 1601- 1609 ,(2008) , 10.1097/QAD.0B013E32830A502E
Ülgen Semaye Fideli, Susan A. Allen, Rosemary Musonda, Stan Trask, Beatrice H. Hahn, Heidi Weiss, Joseph Mulenga, Francis Kasolo, Sten H. Vermund, Grace M. Aldrovandi, Virologic and Immunologic Determinants of Heterosexual Transmission of Human Immunodeficiency Virus Type 1 in Africa AIDS Research and Human Retroviruses. ,vol. 17, pp. 901- 910 ,(2001) , 10.1089/088922201750290023
K. K. GORDON LAN, DAVID L. DEMETS, Discrete sequential boundaries for clinical trials Biometrika. ,vol. 70, pp. 659- 663 ,(1983) , 10.1093/BIOMET/70.3.659
Moira A. McMahon, Janet D. Siliciano, Jun Lai, Jun O. Liu, James T. Stivers, Robert F. Siliciano, Rahul M. Kohli, The Antiherpetic Drug Acyclovir Inhibits HIV Replication and Selects the V75I Reverse Transcriptase Multidrug Resistance Mutation Journal of Biological Chemistry. ,vol. 283, pp. 31289- 31293 ,(2008) , 10.1074/JBC.C800188200
Andrea Lisco, Christophe Vanpouille, Egor P. Tchesnokov, Jean-Charles Grivel, Angélique Biancotto, Beda Brichacek, Julie Elliott, Emilie Fromentin, Robin Shattock, Peter Anton, Robert Gorelick, Jan Balzarini, Christopher McGuigan, Marco Derudas, Matthias Götte, Raymond F. Schinazi, Leonid Margolis, Acyclovir Is Activated into a HIV-1 Reverse Transcriptase Inhibitor in Herpesvirus-Infected Human Tissues Cell Host & Microbe. ,vol. 4, pp. 260- 270 ,(2008) , 10.1016/J.CHOM.2008.07.008
Peter B. Gilbert, Victor G. DeGruttola, Michael G. Hudgens, Steven G. Self, Scott M. Hammer, Lawrence Corey, What Constitutes Efficacy for a Human Immunodeficiency Virus Vaccine that Ameliorates Viremia: Issues Involving Surrogate End Points in Phase 3 Trials The Journal of Infectious Diseases. ,vol. 188, pp. 179- 193 ,(2003) , 10.1086/376449